ClinicalTrials.gg
Not yet recruitingNCT07231523Updated Nov 17, 2025

EFG vs IVIG in TAMG

A Phase 3 interventional study of Efgartigimod + Thymectomy and Intravenous immunglobulin + Thymectomy in Efgartigimod, Intravenous Immunoglobulin and Myasthenia Gravis Associated With Thymoma, sponsored by Shanghai Zhongshan Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Shanghai Zhongshan Hospital · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing efgartigimod alfa in Myasthenia Gravis — 11 open to participants now, 14 under way, 7 of them phase 3. efgartigimod alfa · Myasthenia Gravis.

Planned enrollment
9th of 20
64 · median 55
Started
2025
with 6 others
Phase 3
10 of 20
3 open now
Primary completion
2027-06
later than 10 of 13 live
Registered
19th of 20
by date
Lead sponsor
2 of 20
Shanghai Zhongshan Hospital

Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, this one is the 9th largest by planned enrollment, is one of 7 that started in 2025, is one of 10 in phase 3, reaches primary completion later than 10 of the 13 other live ones, and was the 19th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

11 of the 20 studies testing efgartigimod alfa in Myasthenia Gravis are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About efgartigimod alfa

efgartigimod alfa: first FDA approval 2021 (VYVGART), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing efgartigimod alfa in Myasthenia Gravis, or all of them as a file.
02

Study summary

This study is a prospective, multi-center, randomized controlled study to evaluate the efficacy and safety of efgartigimod (EFG) and intravenous immunoglobulin (IVIG) in the perioperative application for acetylcholine receptor (AChR) antibody-positive thymoma patients with myasthenia gravis in order to provide reliable evidence for clinical decision-making.

03

Conditions studied

  • Efgartigimod
  • Intravenous Immunoglobulin
  • Myasthenia Gravis Associated With Thymoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged >18 years and ≤75 years, with an expected survival time >12 months;
  2. Patients with generalized myasthenia gravis;
  3. MG-ADL ≥6;
  4. Positive for AChR antibody;
  5. Diagnosed with thymoma by enhanced chest CT or MRI;
  6. Patients with thymoma combined with myasthenia gravis who are diagnosed by MDT and need to undergo thymectomy;
  7. Patients with (ASA) grade 1-2;
  8. Able to understand the study situation and sign the .

Exclusion criteria

Exclusion Criteria:

  1. MGFA type V;
  2. Patients who have undergone median sternotomy;
  3. Confirmed history of congestive heart failure; poorly controlled angina pectoris with drug treatment; (ECG) confirmed transmural myocardial infarction; poorly controlled hypertension; valvular heart disease; or high-risk uncontrolled arrhythmia;
  4. Patients with weight loss of more than 5kg in the past month; severe uncontrolled systemic disease, such as active infection or poorly controlled diabetes; patients with hemorrhagic diseases and bleeding tendencies; coagulation dysfunction, bleeding tendency or receiving thrombolytic or anticoagulant therapy; patients with grade II-IV bone marrow suppression;
  5. Females with positive serum pregnancy test or in lactation period, and males and females of childbearing age who are unwilling to use adequate measures during treatment;
  6. History of organ transplantation (including bone marrow transplantation and peripheral stem cell transplantation);
  7. Patients with peripheral nervous system disorders or significant mental disorders and a history of central nervous system disorders;
  8. Patients participating in other clinical studies simultaneously;
  9. Patients who cannot tolerate single-lung ventilation during surgery; severe cardiac complications, cardiovascular decompensation, patients with implanted cardiac pacemakers;
  10. Patients in the acute inflammatory period due to bacterial, viral or other microbial infections; known active infections of (HIV), virus (HBV) or virus (HCV), or known HIV seropositivity;
  11. Patients who have undergone thoracic surgery due to tuberculous pleurisy, mesothelioma, lung disease, or diaphragmatic disease, with ipsilateral lung atelectasis involving one lobe or more than one lobe;
  12. Serum IgG level \<4.5 g/L;
  13. Received biological agents such as rituximab or ibritumomab tiuxetan within 6 months; underwent plasma exchange within 1 month;
  14. Thrombosis, renal impairment or renal failure;
  15. Allergic to human immunoglobulin or have other severe allergic history;
  16. Selective IgA deficiency with anti-IgA antibodies;
  17. Subjects with impaired function of major organs, abnormal blood routine, lung, liver, kidney and cardiac function, and the following laboratory test results:

Blood: white blood cells \<4.0×10\^9/L, (ANC) \<2.0×10\^9/L, count \<100×10\^9/L, \<90g/L; Liver function: serum >1.5 times the upper normal limit; and AST >1.5 times the upper normal limit; Renal function: serum creatinine (SCr) >120 μmol/L, rate (CCr) \<60 ml/min;

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Efgartigimod + Thymectomy

    Combination Product: Efgartigimod + Thymectomy

  • Active comparator
    Intravenous immunglobulin + Thymectomy

    Combination Product: Intravenous immunglobulin + Thymectomy

Interventions

  • Combination productEfgartigimod + Thymectomy

    Drug page: Efgartigimod alfaStudies of Efgartigimod alfaEfgartigimod alfa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients receive weight-based EFG infusions (10 mg/kg; fixed 1200 mg for ≥120 kg) administered over 1 hour once weekly for 4 total doses. If a scheduled infusion is missed, EFG may be administered within 48 hours of the planned time, followed by resumption of the original schedule to complete all 4 infusions. Thymectomy is performed on the day following the second EFG infusion with a permitted ±3-day surgical window.

  • Combination productIntravenous immunglobulin + Thymectomy

    Patients receive weight-based IVIG infusions (400 mg/kg) administered daily for 5 consecutive days. Thymectomy is performed approximately 7 days after completing the final IVIG infusion, with a permitted ±3-day surgical window.

06

What researchers measure

Primary outcomes

  1. Quantitative Myasthenia Gravis (QMG) reduction

    The total QMG score ranges from 0 to 39, with higher scores indicating more severe condition.

    Time frame: From baseline to 2 weeks postoperatively

Secondary outcomes

  1. Myasthenia Gravis Activities of Daily Living (MG-ADL) reduction

    The total MG-ADL score ranges from 0 to 24, with higher scores indicating more severe condition

    Time frame: From baseline to 2 weeks postoperatively

  2. Myasthenia Gravis Composite (MGC) reduction

    The total MGC score ranges from 0 to 50, with higher scores indicating more severe condition.

    Time frame: From baseline to 2 weeks postoperatively

  3. QMG change (1 day preoperatively)

    The change in the QMG score from baseline to 1 day preoperatively

    Time frame: From baseline to 1 day preoperatively

  4. QMG change (1 week postoperatively)

    The change in the QMG score from baseline to 1 week postoperatively

    Time frame: From baseline to 1 week postoperatively

  5. QMG change (1 month postoperatively)

    The change in the QMG score from baseline to 1 month postoperatively

    Time frame: From baseline to 1 month postoperatively

  6. QMG change (2 months postoperatively)

    The change in the QMG score from baseline to 2 months postoperatively

    Time frame: From baseline to 2 months postoperatively

  7. MG-ADL change (1 day preoperatively)

    The change in the MG-ADL score from baseline to 1 day preoperatively

    Time frame: From baseline to 1 day preoperatively

  8. MG-ADL change (1 week postoperatively)

    The change in the MG-ADL score from baseline to 1 week postoperatively

    Time frame: From baseline to 1 week postoperatively

  9. MG-ADL change (1 month postoperatively)

    The change in the MG-ADL score from baseline to 1 month postoperatively

    Time frame: From baseline to 1 month postoperatively

  10. MG-ADL change (2 months postoperatively)

    The change in the MG-ADL score from baseline to 2 months postoperatively

    Time frame: From baseline to 2 months postoperatively

  11. MGC change (1 day preoperatively)

    The change in the MGC score from baseline to 1 day preoperatively

    Time frame: From baseline to 1 day preoperatively

  12. MGC change (1 week postoperatively)

    The change in the MGC score from baseline to 1 week postoperatively

    Time frame: From baseline to 1 week postoperatively

  13. MGC change (1 month postoperatively)

    The change in the MGC score from baseline to 1 month postoperatively

    Time frame: From baseline to 1 month postoperatively

  14. MGC change (2 months postoperatively)

    The change in the MGC score from baseline to 2 months postoperatively

    Time frame: From baseline to 2 months postoperatively

  15. IgG reduction (1 day preoperatively)

    The reduction in the IgG level from baseline to 1 day preoperatively

    Time frame: From baseline to 1 day preoperatively

  16. IgG reduction (1 week postoperatively)

    The reduction in the IgG level from baseline to 1 week postoperatively

    Time frame: From baseline to 1 week postoperatively

  17. IgG reduction (2 weeks postoperatively)

    The reduction in the IgG level from baseline to 2 weeks postoperatively

    Time frame: From baseline to 2 weeks postoperatively

  18. IgG reduction (1 month postoperatively)

    The reduction in the IgG level from baseline to 1 month postoperatively

    Time frame: From baseline to 1 month postoperatively

  19. IgG reduction (2 months postoperatively)

    The reduction in the IgG level from baseline to 2 months postoperatively

    Time frame: From baseline to 2 months postoperatively

  20. AChR-Ab reduction (1 day preoperatively)

    The reduction in the AChR-Ab level from baseline to 1 day preoperatively

    Time frame: From baseline to 1 day preoperatively

  21. AChR-Ab reduction (2 weeks postoperatively)

    The reduction in the AChR-Ab level from baseline to 2 weeks postoperatively

    Time frame: From baseline to 2 weeks postoperatively

  22. AChR-Ab reduction (1 month postoperatively)

    The reduction in the AChR-Ab level from baseline to 1 month postoperatively

    Time frame: From baseline to 1 month postoperatively

  23. Proportion of steroid dose reduction

    The rate of reduction in steroid dose from baseline to 2 months postoperatively

    Time frame: From baseline to 2 months postoperatively

  24. Incidence of myasthenic crisis

    The incidence of postoperative myasthenia gravis crisis, from the start of the trial to the end of the follow-up period

    Time frame: Perioperative period

  25. Incidence of total perioperative complications (≥3)

    The incidence of total perioperative complications assessed by Clavien-Dindo classification

    Time frame: Perioperative period

  26. Incidence of perioperative infection-related complications

    The incidence of perioperative infection-related complications assessed by Clavien-Dindo classification.

    Time frame: Perioperative period

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Jun 2027, 18 months later.

Of 51 phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 43. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Nov 17, 2025
StartEst.
Dec 1, 2025
Primary completionEst.
Jun 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07231523
Collaborators
The Affiliated Hospital of Xuzhou Medical University, First Affiliated Hospital of Wenzhou Medical University, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Tang-Du Hospital, West China Hospital, Second Affiliated Hospital of Soochow University, Huashan Hospital, The Affiliated Brain Hospital of Nanjing Medical University, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Wuhan TongJi Hospital
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Dec 1, 2025 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 17, 2025

Study contacts

Jianyong Ding
Contact
ding.jianyong@zs-hospital.sh.cn
+86 18616881268

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efgartigimod alfa

Start the discussion